Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 56 references it cites were found in a registry or an index; 28 of the 57 sources its claims cite were checked for support.

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System

Open access
Raschi, Emanuel, Fusaroli, Michele, Massari, Francesco, Mollica, Veronica, Repaci, Andrea, Ardizzoni, Andrea, Poluzzi, Elisabetta, Pagotto, Uberto, Di Dalmazi, Guido · 2022 · The Journal of Clinical Endocrinology & Metabolism

Abstract

Context: Adrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component. Objective: This work aimed to describe the spectrum of drug-induced AI through adverse drug event reports received by the US Food and Drug Administration (FDA). Methods: A retrospective disproportionality analysis reporting trends of drug-induced AI was conducted on the FDA Adverse Event Reporting System (FAERS) (> 15 000 000 reports since 2004). AE reports were extracted from FAERS over the past 2 decades. Interventions included cases containing any of the preferred terms in the Medical Dictionary for Regulatory Activities describing AI, and signals of disproportionate reporting for drugs recorded in 10 or more cases as primary suspect. Results: We identified 8496 cases of AI: 97.5% serious, 41.1% requiring hospitalization. AI showed an exponential increase throughout the years, with 5282 (62.2%) cases in 2015 to 2020. We identified 56 compounds associated with substantial disproportionality: glucocorticoids (N = 1971), monoclonal antibodies (N = 1644, of which N = 1330 were associated with immune checkpoint inhibitors—ICIs), hormone therapy (N = 291), anti-infectives (N = 252), drugs for hypercortisolism or adrenocortical cancer diagnosis/treatment (N = 169), and protein kinase inhibitors (N = 138). Cases of AI by glucocorticoids were stable in each 5-year period (22%-27%), whereas those by monoclonal antibodies, largely ICIs, peaked from 13% in 2010 to 2015 to 33% in 2015 to 2020. Conclusion: We provide a comprehensive insight into the evolution of drug-induced AI, highlighting the heterogeneous spectrum of culprit drug classes and the emerging increased reporting of ICIs. We claim for the urgent identification of predictive factors for drug-induced AI, and the establishment of screening and educational protocols for patients and caregivers.

Overview

CoChat Summary

TL;DR

This FAERS disproportionality analysis identified 8,496 drug-induced adrenal insufficiency (AI) cases, mostly serious, with glucocorticoids reported stably and monoclonal antibodies/immune checkpoint inhibitors rising sharply in 2015-2020. It describes a heterogeneous culprit drug spectrum and calls for screening, education, and identification of predictive factors.

Key findings

  • Among 10,400,290 retained FAERS reports, 8,496 AI cases were identified; 97.5% were serious, 41.1% required hospitalization, and 5,282 (62.2%) occurred in 2015-2020, showing an exponential increase over time.
  • 56 compounds had disproportionate reporting: glucocorticoids (N = 1971), monoclonal antibodies (N = 1644; ICIs N = 1330), hormone therapy (N = 291), anti-infectives (N = 252), drugs for hypercortisolism/adrenocortical cancer (N = 169), and protein kinase inhibitors (N = 138).
  • Glucocorticoid-related AI remained stable across 5-year periods (22%-27%), whereas monoclonal antibodies rose from 13% in 2010-2015 to 33% in 2015-2020; ICIs showed a steady increase (N = 433 in 2020).
  • In 2015-2020, the most frequently reported drugs were nivolumab (N = 612), pembrolizumab (N = 270), ipilimumab (N = 230), hydrocortisone (N = 206), triamcinolone (N = 152), and fluticasone (N = 150); monoclonal antibody cases included 866 hospitalizations (53%) and 172 deaths (11%), versus 513 (27%) and 69 (3.6%) for glucocorticoids.

Methods

  • Retrospective disproportionality analysis of FAERS data up to 2020, after deduplication, retaining 10,400,290 reports; AI cases were identified using MedDRA preferred terms under the high-level term “adrenal cortical hypofunctions,” excluding low-specificity terms, and exposure was restricted to drugs recorded as primary suspect.
  • Case/noncase reporting odds ratios (RORs) with 95% CIs were calculated; signals required the lower 95% CI > 1, at least 10 cases, and Bonferroni correction, using R version 4.1.1 and valid percentages for missing data.

Limitations

  • The paper states traditional pharmacovigilance limitations: causality cannot be inferred (ROR is not a risk measure), information quality may be incomplete (eg, laboratory/clinical validation), and lack of denominators prevents incidence calculation; increased reporting may reflect missing data before 2010, mandatory trial reporting, greater awareness, and expanding anticancer drug approvals.
  • The paper also notes reporting biases over time, including underreporting, stimulated reporting/notoriety bias, the Weber effect, and competition bias; lack of disproportionality should not be interpreted as safety, and patients may receive multiple medications potentially affecting adrenal function, though the analysis was restricted to suspect drugs.
  • Evident from the design: FAERS spontaneous reports cannot control for confounders or verify diagnoses, and the findings describe reporting patterns rather than confirmed drug-induced AI risk.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/clinem/dgac359

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Evolution of cumulative number of reports (cases of adrenal hypofunctions for a given pharmacological class/total cases of adrenal hypofunction per year) by reporting year. The timeline is shown as half-decade, with the first one comprising only the period 2004 to 2005.
Figure 1. Evolution of cumulative number of reports (cases of adrenal hypofunctions for a given pharmacological class/total cases of adrenal hypofunction per year) by reporting year. The timeline is shown as half-decade, with the first one comprising only the period 2004 to 2005.CC BY-NC-ND · PubMed Central
Figure 2. Heat map (disproportionality analysis). Drugs with statistically significant disproportionality reported in at least 20 cases as primary suspect are shown. The size of the circles is proportional to the number of cases.
Figure 2. Heat map (disproportionality analysis). Drugs with statistically significant disproportionality reported in at least 20 cases as primary suspect are shown. The size of the circles is proportional to the number of cases.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

21 Valid · 1 Not valid · 13 Not checked · 66 Own results and interpretations

64 more claims · 7 with their cited sources checked

Create a free account to see all 101 claims and to verify the 6 references still open.

See all claims — free account
  • It may state two separate claims as one. 19
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 56 references

Cited by

See all 17

Metadata

Authors
Raschi, E., Fusaroli, M., Massari, F., Mollica, V., Repaci, A., Ardizzoni, A., Poluzzi, E., Pagotto, U., & Di Dalmazi, G.
Affiliations
  • University of Bologna (IT)
  • IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
  • Division of Endocrinology and Diabetes Prevention and Care Unit, IRCCS Azienda Ospedaliero–Universitaria di Bologna , Bologna 40138 , Italy
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2022-06-15
Volume
107
Issue
8
Pages
e3107-e3114
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4282970174
Cited by
17
References
56
Citations by year
2026: 3 · 2025: 2 · 2024: 7 · 2023: 3 · 2022: 2
FWCI
2.27
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
Keywords
drug-induced adrenal insufficiency, adverse drug reactions, immune checkpoint inhibitors, glucocorticoids, monoclonal antibodies, disproportionality analysis, FDA Adverse Event Reporting System, pharmacovigilance, hypercortisolism, adrenocortical carcinoma, protein kinase inhibitors, hormone therapy, anti-infective agents
MeSH terms
Antineoplastic Agents, Immunological, Adrenal Insufficiency, Antibodies, Monoclonal, Humans, Retrospective Studies, United States, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. https://app.cochat.ai/papers/10.1210/clinem/dgac359
The paper
Raschi, E., Fusaroli, M., Massari, F., Mollica, V., Repaci, A., Ardizzoni, A., Poluzzi, E., Pagotto, U., & Di Dalmazi, G. (2022). The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac359

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.